Alpha Cognition Launches ZUNVEYL for Alzheimer’s Treatment
Alpha Cognition Inc. has officially launched ZUNVEYL, a new treatment for mild to moderate Alzheimer’s disease—marking a major milestone in the company’s mission to support patients and caregivers. Backed by a seasoned commercial team and a nationwide salesforce, Alpha Cognition is focused on reaching the long-term care market, the largest and most critical segment for Alzheimer’s care. With a tailored strategy in place, ZUNVEYL is set to bring much-needed hope and innovation to a $2 billion market.
Alpha Cognition Launches ZUNVEYL for Alzheimer’s Treatment